Literature DB >> 29738626

Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail.

T Hank1, U Hinz1, I Tarantino1, J Kaiser1, W Niesen1, F Bergmann2, T Hackert1, M W Büchler1, O Strobel1.   

Abstract

BACKGROUND: The definition of resection margin (R) status in pancreatic cancer is under debate. Although a margin of at least 1 mm is an independent predictor of survival after resection for pancreatic head cancer, its relevance to pancreatic body and tail cancers remains unclear. This study aimed to validate R status based on a 1-mm tumour-free margin as a prognostic factor for resected adenocarcinoma involving the pancreatic body and tail.
METHODS: Patients who underwent distal or total pancreatectomy for adenocarcinomas of the pancreatic body and tail between January 2006 and December 2014 were identified from a prospective database. Resection margins were evaluated using a predefined cut-off of 1 mm. Rates of R0, R1 with invasion within 1 mm of the margin (R1 less than 1 mm), and R1 with direct invasion of the resection margin (R1 direct) were determined, and overall survival in each group assessed by Kaplan-Meier analysis. Univariable and multivariable Cox regression analyses were performed to identify predictors of survival.
RESULTS: R0 resection was achieved in 107 (23·5 per cent) and R1 in 348 (76·5 per cent) of 455 patients. Among R1 resections, invasion within 1 mm of the margin was found in 104 (22·9 per cent) and direct invasion in 244 (53·6 per cent). The R0 rate was 28·9 per cent after distal and 18·6 per cent after total pancreatectomy. In the total cohort, median survival times for patients with R0, R1 (less than 1 mm) and R1 (direct) status were 62·4, 24·6 and 17·2 months respectively, with 5-year survival rates of 52·6, 16·8 and 13·0 per cent (P < 0·001). In patients who received adjuvant chemotherapy, respective median survival times were 68·6, 32·8 and 21·4 months, with 5-year survival rates of 56, 22 and 16·0 per cent (P < 0·001). In multivariable analysis, R status was independently associated with survival.
CONCLUSION: A cut-off of at least 1 mm for evaluation of resection margins is an independent determinant of survival after resection of adenocarcinomas of the pancreatic body and tail.
© 2018 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29738626     DOI: 10.1002/bjs.10842

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  14 in total

1.  Impact of Neoadjuvant Therapy on Survival Following Margin-Positive Resection for Pancreatic Cancer.

Authors:  Asmita Chopra; Mazen Zenati; Melissa E Hogg; Herbert J Zeh; David L Bartlett; Nathan Bahary; Amer H Zureikat; Joal D Beane
Journal:  Ann Surg Oncol       Date:  2021-05-23       Impact factor: 5.344

Review 2.  [Surgical treatment of pancreatic cancer-What is new?]

Authors:  Thomas Schmidt; Orlin Belyaev; Waldemar Uhl; Christiane J Bruns
Journal:  Chirurg       Date:  2022-03-31       Impact factor: 0.955

3.  Pancreaticoduodenectomy for pancreatic head cancer with cavernous transformation of the portal vein: a case report.

Authors:  Naohiro Hirano; Masahiro Iseki; Takanori Morikawa; Yuuichiro Umino; Shuichi Aoki; Koetsu Inoue; Shun Nakayama; Takayuki Miura; Kunihiro Masuda; Masaharu Ishida; Hideo Ohtsuka; Masamichi Mizuma; Kei Nakagawa; Kiyoshi Kume; Atsushi Masamune; Takashi Kamei; Michiaki Unno
Journal:  Surg Case Rep       Date:  2022-06-30

Review 4.  Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground.

Authors:  Stefano Crippa; Giulio Belfiori; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Updates Surg       Date:  2021-07-31

Review 5.  What do surgeons need to know about the mesopancreas.

Authors:  Eduardo de Souza M Fernandes; Oliver Strobel; Camila Girão; Jose Maria A Moraes-Junior; Orlando Jorge M Torres
Journal:  Langenbecks Arch Surg       Date:  2021-06-12       Impact factor: 3.445

6.  Impact of different surgical procedures on survival outcomes of patients with adenocarcinoma of pancreatic neck.

Authors:  Zhenjiang Zheng; Chunlu Tan; Yonghua Chen; Jie Ping; Mojin Wang
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

Review 7.  An update on treatment options for pancreatic adenocarcinoma.

Authors:  Aurélien Lambert; Lilian Schwarz; Ivan Borbath; Aline Henry; Jean-Luc Van Laethem; David Malka; Michel Ducreux; Thierry Conroy
Journal:  Ther Adv Med Oncol       Date:  2019-09-25       Impact factor: 8.168

8.  Arterial Divestment and Resection in Post-neoadjuvant Pancreatic Adenocarcinoma.

Authors:  Yugal Limbu; Sujan Regmee; Roshan Ghimire; Dhiresh Kumar Maharjan; Prabin Bikram Thapa
Journal:  Cureus       Date:  2021-12-08

Review 9.  Conversion Surgery for Advanced Pancreatic Cancer.

Authors:  Thomas Hank; Oliver Strobel
Journal:  J Clin Med       Date:  2019-11-12       Impact factor: 4.241

Review 10.  [Surgery for periampullary pancreatic cancer].

Authors:  Thomas Hank; Ulla Klaiber; Klaus Sahora; Martin Schindl; Oliver Strobel
Journal:  Chirurg       Date:  2021-07-14       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.